Lymphoma

News, features, and commentary about cancer-related issues

News, features, and commentary about cancer-related issues

Here's how the medical team diagnosed and treated the rare inflammatory skin disorder

Approval of glofitamab was based on a phase I/II study that showed a 56% overall response rate

News, features, and commentary about cancer-related issues

Patients with depression alone had the worst overall survival

All patients had progressed on BTK inhibitors and most had failed venetoclax

PET-negative patients after chemoimmunotherapy fared well with observation alone

The CAR T-cell therapy led to significantly longer overall survival

SWOG trial had goal of "harmonizing" treatment in adults, children with advanced-stage disease

News, features, and commentary about cancer-related issues

Hodgkin's is one of the more rare lymphomas, but tends to be very treatable

Epcoritamab is for patients who have received two or more lines of systemic therapy

Results will likely "encourage a practice change," editorialists say